The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: ILD with a granulomatous component (see also Im)
Publications
Pulmonary Sarcoidosis following Etanercept Treatment.
Case reports in rheumatology 2012;2012;724013 — 2012 — 724013
Ishiguro T, Takayanagi N, Kurashima K, Matsushita A, Harasawa K, Yoneda K, Tsuchiya N, Miyahara Y, Yamaguchi S, Yano R, Tokunaga D, Saito H, Ubukata M, Yanagisawa T, Sugita Y, Kawabata Y
Development of sarcoidosis during etanercept therapy.
Internal medicine (Tokyo, Japan) 2008;47;1021-5 — 2008 — 1021-5
Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 May;18;651-5 — 2005 May — 651-5
Lung injury linked to etanercept therapy.
Chest 2002 Nov;122;1858-60 — 2002 Nov — 1858-60